Short answer
Tarsus Pharmaceuticals, Inc. (TARS) filed an 8-K current report with the SEC on September 10, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Acquisition of Alkeus completed September 4, 2026, adding gildeuretinol through a wholly owned subsidiary.
Tarsus Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Acquisition of Alkeus completed September 4, 2026, adding gildeuretinol through a wholly owned subsidiary
- Up-front consideration: $270M cash plus 2,908,692 Tarsus shares, subject to adjustments
- Additional milestones up to $350M, including $250M upon U.S. regulatory approval and $100M upon first U.S. sale
- Future revenue sharing in low-to-mid single digits of worldwide gildeuretinol net sales
- Registration rights for certain Alkeus equityholders became effective at closing, creating potential future share-sale overhang
Item 8.01 · Other Events
- Tarsus completed an acquisition on September 4, 2026
- Transaction completion marks a material strategic change requiring review of Exhibit 99.1
- Investors should assess the acquired asset, purchase consideration, and expected financial impact in the attached release
Item EX-99.1 · Exhibit EX-99.1
- Acquisition of Alkeus completed, adding worldwide rights to Phase 3 gildeuretinol for Stargardt disease
- Pipeline expands into rare retinal disease with no FDA-approved therapy and estimated 86,000 U.S. patients
- NORTHSTAR Phase 3 topline data anticipated in 2029, extending the program’s key value catalyst
- Gildeuretinol studied in more than 400 individuals and holds four FDA designations
- Strategic shift strengthens Tarsus’ eye-care pipeline but adds substantial late-stage clinical and regulatory execution risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tarsus Pharmaceuticals, Inc. 8-K filings
Get the next TARS 8-K as it lands
Follow TARS for push alerts, or ask the research agent what this filing means.